Alcobra Ltd (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced that corporate presentations will be provided at two conferences focused on Central Nervous System (CNS) disorders in April.

10th Annual Neurotech Investing & Partnering Conference
Date:   Tuesday, April 7
Time:   3:30pm Pacific Time
Location:   Hotel Nikko, San Francisco
Presenter: David Baker, Chief Commercial Officer
Conference Information:
Neurology Innovation Conference
Date:   Sunday, April 19
Time:   3:30pm Eastern Time
Location:   Embassy Suites, Washington DC
Presenter: Jonathan Rubin, MD, MBA, Chief Medical Officer
Conference Information:

(Original Source)

Shares of Alcobra Ltd closed last Thursday at $5.69 . ADHD has a 1-year high of $22.19 and a 1-year low of $3.12. The stock's 50-day moving average is $6.58 and it's 200-day moving average is $6.26.

On the ratings front, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on ADHD, with a price target of $10, The current price target implies an upside of 75.7% from current levels, In a report issued on February 23. The current price target implies an upside of 75.7% from current levels

According to, Chattopadhyay has a total average return of 12.2%, a 42.7% success rate, and is ranked #423 out of 3568 analysts.

Alcobra Ltd is a biopharmaceutical company which engaged in the development and commercialization of its proprietary oral drug candidate, MDX, to treat ADHD and other cognitive dysfunctions including Fragile X Syndrome.